An overview of HER2 - PubMed (original) (raw)
Review
. 2001 Dec;28(6 Suppl 18):3-11.
Affiliations
- PMID: 11774200
Review
An overview of HER2
C Lohrisch et al. Semin Oncol. 2001 Dec.
Abstract
HER2 is a transmembrane growth factor receptor found in normal and malignant breast epithelial cells. Phosphorylation of the intracellular tyrosine kinase results in intracellular signaling and activation of genes involved in cell growth. Overexpression of HER2 has independent prognostic significance in early breast cancer and may also predict response to hormonal and cytotoxic therapies, although this latter role is less well studied. Prospective stratification of HER2 status in current clinical trials may more accurately delineate these roles. Anti-HER2 therapy, using a humanized monoclonal antibody, has enhanced survival when given with chemotherapy compared with chemotherapy alone in patients with metastatic HER2-overexpressing breast cancer. A potential limitation to its use in the adjuvant setting is the increased incidence of cardiotoxicity in patients treated either concurrently or previously with anthracyclines; carefully designed prospective adjuvant trials are currently being launched. HER2 is a relatively new prognostic marker and holds promise for predicting response to various therapies and for target-specific therapy.
Copyright 2001 by W.B. Saunders Company.
Similar articles
- HER2/neu role in breast cancer: from a prognostic foe to a predictive friend.
Ferretti G, Felici A, Papaldo P, Fabi A, Cognetti F. Ferretti G, et al. Curr Opin Obstet Gynecol. 2007 Feb;19(1):56-62. doi: 10.1097/GCO.0b013e328012980a. Curr Opin Obstet Gynecol. 2007. PMID: 17218853 Review. - Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.
Scaltriti M, Rojo F, Ocaña A, Anido J, Guzman M, Cortes J, Di Cosimo S, Matias-Guiu X, Ramon y Cajal S, Arribas J, Baselga J. Scaltriti M, et al. J Natl Cancer Inst. 2007 Apr 18;99(8):628-38. doi: 10.1093/jnci/djk134. J Natl Cancer Inst. 2007. PMID: 17440164 - Unraveling the biologic and clinical complexities of HER2.
Park JW, Neve RM, Szollosi J, Benz CC. Park JW, et al. Clin Breast Cancer. 2008 Oct;8(5):392-401. doi: 10.3816/CBC.2008.n.047. Clin Breast Cancer. 2008. PMID: 18952552 Review. - Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer.
Hortobagyi GN. Hortobagyi GN. Semin Oncol. 2001 Dec;28(6 Suppl 18):43-7. Semin Oncol. 2001. PMID: 11774205 Review. - [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
Dank M. Dank M. Orv Hetil. 2001 Nov 18;142(46):2563-8. Orv Hetil. 2001. PMID: 11770175 Review. Hungarian.
Cited by
- 17q Gain in Neuroblastoma: A Review of Clinical and Biological Implications.
Mlakar V, Dupanloup I, Gonzales F, Papangelopoulou D, Ansari M, Gumy-Pause F. Mlakar V, et al. Cancers (Basel). 2024 Jan 12;16(2):338. doi: 10.3390/cancers16020338. Cancers (Basel). 2024. PMID: 38254827 Free PMC article. Review. - Unlocking New Avenues in Breast Cancer Treatment: The Synergy of Kinase Inhibitors and Immunotherapy.
Bravo MJ, Burgos-Molina AM, García-Aranda M, Redondo M, Téllez T. Bravo MJ, et al. Cancers (Basel). 2023 Nov 21;15(23):5499. doi: 10.3390/cancers15235499. Cancers (Basel). 2023. PMID: 38067203 Free PMC article. Review. - Advanced renal pelvis carcinoma patient with an ERBB2 insertion mutation: a case report.
Shang P, Lou C, Yin L, Tao C, Dong Y, Yang G, Yuan Z. Shang P, et al. J Int Med Res. 2023 Nov;51(11):3000605231204502. doi: 10.1177/03000605231204502. J Int Med Res. 2023. PMID: 37917812 Free PMC article. - Development of the Sensing Platform for Protein Tyrosine Kinase Activity.
Wei LY, Lin W, Leo BF, Kiew LV, Chang CC, Yuan CJ. Wei LY, et al. Biosensors (Basel). 2021 Jul 15;11(7):240. doi: 10.3390/bios11070240. Biosensors (Basel). 2021. PMID: 34356711 Free PMC article. - Expression of Podoplanin in Mammary Cancers in Female Dogs.
Borecka P, Ciaputa R, Janus I, Piotrowska A, Ratajczak-Wielgomas K, Kmiecik A, Podhorska-Okolów M, Dzięgiel P, Nowak M. Borecka P, et al. In Vivo. 2020 Jan-Feb;34(1):213-223. doi: 10.21873/invivo.11763. In Vivo. 2020. PMID: 31882481 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous